GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Cyclically Adjusted PB Ratio

BriaCell Therapeutics (TSX:BCT) Cyclically Adjusted PB Ratio : 0.21 (As of Jun. 25, 2025)


View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-06-25), BriaCell Therapeutics's current share price is C$4.01. BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2025 was C$18.84. BriaCell Therapeutics's Cyclically Adjusted PB Ratio for today is 0.21.

The historical rank and industry rank for BriaCell Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

TSX:BCT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.22
Current: 0.22

During the past years, BriaCell Therapeutics's highest Cyclically Adjusted PB Ratio was 0.22. The lowest was 0.00. And the median was 0.00.

TSX:BCT's Cyclically Adjusted PB Ratio is ranked better than
81.26% of 683 companies
in the Biotechnology industry
Industry Median: 1.49 vs TSX:BCT: 0.22

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BriaCell Therapeutics's adjusted book value per share data for the three months ended in Apr. 2025 was C$2.562. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$18.84 for the trailing ten years ended in Apr. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


BriaCell Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for BriaCell Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Cyclically Adjusted PB Ratio Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.12 0.23 0.52 0.50

BriaCell Therapeutics Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.46 0.50 0.69 0.33 0.32

Competitive Comparison of BriaCell Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, BriaCell Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

BriaCell Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

BriaCell Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.01/18.84
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BriaCell Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2025 is calculated as:

For example, BriaCell Therapeutics's adjusted Book Value per Share data for the three months ended in Apr. 2025 was:

Adj_Book=Book Value per Share/CPI of Apr. 2025 (Change)*Current CPI (Apr. 2025)
=2.562/129.1809*129.1809
=2.562

Current CPI (Apr. 2025) = 129.1809.

BriaCell Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201507 78.474 100.579 100.789
201510 60.053 100.500 77.191
201601 39.053 100.184 50.356
201604 72.800 101.370 92.773
201607 51.350 101.844 65.134
201610 97.227 102.002 123.134
201701 81.636 102.318 103.069
201704 88.292 103.029 110.704
201707 39.667 103.029 49.736
201710 49.760 103.424 62.152
201801 23.360 104.056 29.000
201804 85.457 105.320 104.818
201807 35.457 106.110 43.166
201810 13.083 105.952 15.951
201901 -22.361 105.557 -27.365
201904 19.545 107.453 23.497
201907 -20.523 108.243 -24.493
201910 -22.417 107.927 -26.831
202001 -61.688 108.085 -73.728
202004 -80.667 107.216 -97.193
202007 -101.146 108.401 -120.535
202010 -87.314 108.638 -103.824
202101 -90.588 109.192 -107.172
202104 34.392 110.851 40.079
202107 34.060 112.431 39.134
202110 67.196 113.695 76.348
202201 56.639 114.801 63.733
202204 55.900 118.357 61.012
202207 12.910 120.964 13.787
202210 13.668 121.517 14.530
202301 -1.661 121.596 -1.765
202304 -7.676 123.571 -8.024
202307 -4.685 124.914 -4.845
202310 3.503 125.310 3.611
202401 -10.175 125.072 -10.509
202404 -7.659 126.890 -7.797
202407 -2.680 128.075 -2.703
202410 2.306 127.838 2.330
202501 1.759 127.443 1.783
202504 2.562 129.181 2.562

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BriaCell Therapeutics  (TSX:BCT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


BriaCell Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Traded in Other Exchanges
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Executives
Jamieson Bondarenko Director
Marc Lustig 10% Security Holder, Director
Gadi Levin Senior Officer
William Williams Director, Senior Officer

BriaCell Therapeutics Headlines

No Headlines